Autism Spectrum Disorders Clinical Trial
— GIETSAOfficial title:
Interactive Guidance Therapy With Video Feed-back of Parent and Child With Autism Spectrum Disorder
The purpose of this study is to assess the effect of Interactive Guidance Therapy with video feed back (IGT) of parent and child with Autism Spectrum Disorder, under three years of age, using a Single Case Experimental Design (SCED) with multiple baseline across subjects, multicentric, randomized, with multiple replications, blinded scored
Status | Recruiting |
Enrollment | 24 |
Est. completion date | January 2026 |
Est. primary completion date | October 2025 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Months to 3 Years |
Eligibility | Inclusion Criteria: - 18 months to 3 years child at screening - Child with a diagnosis of Autism Spectrum Disorder (DSM 5) or pervasive Developmental Disorder (ICD 10) - Child with ADI R and ADOS-2 fulfilling the criteria for TSA / PDD at diagnosis - Developmental age > 12 months in motility with the Brunet-Lézine test - Child with availability of parent most present in daily life, only this parent participating directly in play sessions - Signed Informed consent form by both parents - Patient affiliated to the health insurance system Exclusion Criteria: - Level of language in French of parents insufficient to benefit from the care and fill in the questionnaires - Psychiatric parental pathology interfering with interactions with the child, qualitatively assessed by the referring psychiatrist - Severe sensory illness of the child (blindness, deafness, degenerative disease) |
Country | Name | City | State |
---|---|---|---|
France | Hôpital Saint Eloi | Montpellier | |
France | Hôpital Ville Evrard | Montreuil | |
France | Hôpital Necker Enfants Malades | Paris | |
France | Hôpital Pitié Salpétriere | Paris |
Lead Sponsor | Collaborator |
---|---|
Assistance Publique - Hôpitaux de Paris | Ville Evrard Hospital |
France,
1. McDonough S. Interaction guidance. Treat Parent-infant Relatsh Probl Strateg Interv. 2004;79-96.
2. McDonough SC. Promoting positive early parent-infant relationships through interaction guidance. Child Adolesc Psychiatr Clin N Am. 1995;4(3):661-72.
Rusconi-Serpa S, Sancho Rossignol A, McDonough SC. Video feedback in parent-infant treatments. Child Adolesc Psychiatr Clin N Am. 2009 Jul;18(3):735-51. doi: 10.1016/j.chc.2009.02.009. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Percentage of time spent in a joint attention situation | Coordinated Joint Attention (COJ) rate is evaluated during the parents-child play-time | Up to 15 months | |
Primary | Percentage of time spent in a joint attention situation | Supported Joint Attention (SUJ) rate is evaluated during the parents-child play-time | Up to 15 months | |
Secondary | Parent-child interactive features/ joint attention | - SUJ and COJ rate initiated by child | Up to 15 months | |
Secondary | Parent-child interactive features / DCMA scale | - DCMA: dyadic communication measure in autism | Up to 15 months | |
Secondary | Parent-child interactive features / Parental synchrony | - number of parental responses in synchrony with child | Up to 15 months | |
Secondary | Parent-child interactive features / Communication | - Number conversational turns of speech between the child and the parent | Up to 15 months | |
Secondary | Parent-child interactive features / Initiation of communication | - Initiation of communication by the child with the parent : in proportion to the child's acts of communication | Up to 15 months | |
Secondary | Child development / MSEL | - MSEL : is Mullen Scale of Early Learning evaluated at inclusion visit, guidance session 1, guidance session 10 and guidance session 15 | Up to 15 months | |
Secondary | Child development / CDI | - CDI is Child Development Inventory evaluated at inclusion visit, guidance session 1, guidance session 10 and guidance session 15 | Up to 15 months | |
Secondary | Child development / IFDC | - IFDC is French adaptation of MacArthur-Bates Communicative Development Inventories evaluated at inclusion visit, guidance session 1, guidance session 10 and guidance session 15 | Up to 15 months | |
Secondary | Autistic Symptoms / CARS | CARS is Childhood Autism Rating Scale evaluated at inclusion visit, guidance session 1, guidance session 10 and guidance session 15 | Up to 15 months | |
Secondary | Autistic Symptoms ECAR | ECA R is "Evaluation des comportements autistiques Révisée" Scale evaluated at inclusion visit, guidance session 1, guidance session 10 and guidance session 15 | Up to 15 months | |
Secondary | Autistic Symptoms ADOS-2 | ADOS-2 is Autism diagnostic observation Schedule evaluated at inclusion visit, guidance session 1, guidance session 10 and guidance session 15 | Up to 15 months | |
Secondary | Autistic Symptoms ADIR | ADI R is Autism Diagnosis Interview Revised evaluated at inclusion visit, guidance session 1, guidance session 10 and guidance session 15 | Up to 15 months | |
Secondary | Adaptive behavior of the child | Vineland 2 Scale evaluated at inclusion visit, guidance session 1, guidance session 10 and guidance session 15 | Up to 15 months | |
Secondary | Change process | Psychotherapy Process Q-set evaluated at baseline visit 1 and last baseline visit (depend of randomization), guidance session 1 and guidance session 10 | Up to 15 months | |
Secondary | Content analysis of guidance session by parent | Targeted interview of parents with the psychologist on the content of guidance session | At 16 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT02625116 -
ELENA Cohort: A Long-term Longitudinal Study in a Pediatric Sample With Autism Spectrum Disorders
|
||
Not yet recruiting |
NCT06381856 -
Improving Participation of Autistic Children and Adolescents in the Habilitation Process
|
||
Recruiting |
NCT02280746 -
Gluten for Autism Spectrum Disorders
|
N/A | |
Completed |
NCT01945957 -
Brain Imaging of Intranasal Oxytocin Treatment in Autism
|
Phase 1 | |
Completed |
NCT01661855 -
A Pilot Study of Riluzole Versus Placebo in the Treatment of Children and Adolescents With ASD
|
Phase 2 | |
Completed |
NCT01592747 -
Withdrawal Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified Previously Treated With Memantine
|
Phase 2 | |
Completed |
NCT01691066 -
Pivotal Response Treatment for Infants At-Risk for Autism Spectrum Disorder
|
N/A | |
Completed |
NCT01694667 -
Omega-3 Fatty Acids for Hyperactivity Treatment in Autism Spectrum Disorder
|
Phase 2 | |
Completed |
NCT01780090 -
Handheld Technology for Speech Development in Students With Autism
|
N/A | |
Active, not recruiting |
NCT01417026 -
Intranasal Oxytocin and Learning in Autism
|
Phase 2 | |
Enrolling by invitation |
NCT01364818 -
Brain Connectivity in Neurodevelopmental Disorders in Response to Treatment
|
N/A | |
Completed |
NCT01695200 -
Omega-3 Fatty Acids in Autism Spectrum Disorders
|
Phase 4 | |
Completed |
NCT02300597 -
Internet-based Support for Young People With ADHD and Autism - a Controlled Study
|
N/A | |
Completed |
NCT01675414 -
Understanding Gastrointestinal Conditions in Children With Autism Spectrum Disorder (ASD)
|
N/A | |
Not yet recruiting |
NCT00695812 -
The Development of Younger Siblings of Children With Autism Now at 10 Years of Age
|
N/A | |
Recruiting |
NCT05910502 -
Project AFECT (Autism Family Empowerment Coaching and Training Program)
|
N/A | |
Completed |
NCT02081027 -
Pilot Study of Riluzole for Drug-Refractory Irritability in Autism Spectrum Disorders
|
Early Phase 1 | |
Completed |
NCT02797379 -
The Development of a Psychoeducational Tool to Manage Anxiety in People With Autism Spectrum Disorders
|
N/A | |
Terminated |
NCT01730079 -
Near Infrared Spectroscopy in Children With Autism and ADHD
|
||
Completed |
NCT01603225 -
Transcranial Direct Current Stimulation and Autism
|